Endocrine abnormality in paraneoplastic syndrome. Issue 3 (May 2022)

• Record Type: Journal Article
• Authors: Onyema, Michael C.; Drakou, Eftychia E.; Dimitriadis, Georgios K.
• Is Part Of: Best practice & research. Volume 36:Issue 3(2022)
• Publication Date: 2022-05
• Subjects: paraneoplastic syndrome -- endocrine -- peptides -- cytokines -- hormones -- pituitary autoimmunity; Endocrine glands -- Diseases -- Periodicals; Metabolism -- Disorders -- Periodicals; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1016/j.beem.2022.101621
• Languages: English
• ISSNs: 1521-690X

Abstract

Abstract : Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.